Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

By HongJiang Li, Staff Writer, and BioCentury Staff

Oct 6, 2020 | 2:38 AM GMT

BridgeBio reacquiring Eidos spinout
Four years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already own. Eidos’ lead program acoramidis (AG-10) is in Phase III testing to